Filter News

TrovaGene Schedules Release Of First Quarter 2016 Financial Results And Investor Conference Call

Published: May 03, 2016

SAN DIEGO, May 3, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 on Tuesday, May 10, 2016 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).

A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Trovagene's senior management team will host a conference call on Tuesday, May, 10, 2016 at 5:00 p.m. Eastern Daylight Time (2:00 p.m. Pacific Daylight Time) to discuss the results and update investors on the Company's progress.

A live webcast of the call will be available online at http://trovagene.investorroom.com/events. To access the conference call, please dial (888) 347-6081 (domestic), (412) 902-4285 (international), or (855) 669-9657 (Canada), conference ID# 10084934. To access the telephone replay of the call, dial (877) 344-7529 (domestic), (412) 317-0088 (international), or (855) 669-9658 (Canada), replay ID# 10084934. The replay will be available one hour after the conclusion of the call. The webcast and telephone replay will be archived on the Company's website following the conference. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Contact






Investor Relations


Media Relations

David Moskowitz

Vice President, Investor Relations


Jody LoMenzo

Corporate Practice Counsel

Trovagene, Inc.


Inventiv Health Public Relations

858-952-7593


212-364-0458

ir@trovagene.com


Jody.LoMenzo@inventivhealth.com

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-schedules-release-of-first-quarter-2016-financial-results-and-investor-conference-call-300261632.html

SOURCE Trovagene, Inc.

Back to news